Navigation Links
Helix Biopharma to Present L-DOS47 Lung Cancer Research Findings at,the Fourth International Conference on Tumor Microenvironment in,Florence, Italy

mor Microenvironment conference website, and the reference to such website in this News Release does not constitute an endorsement by Helix of that or any other website. This News Release contains certain forward-looking statements regarding potential cancer therapeutics under development by the Company, and in particular, regarding L-DOS47. Forward-looking statements can be identified by the use of forward-looking terminology such as "potential", "is thought", "is believed", "new", "will", "theorized", or variations thereon or comparable terminology referring to future events or results.

Forward looking statements are statements about the future and are inherently uncertain, and Helix's
actual results could differ materially from those anticipated in these forward-looking statements as a result of numerous factors, including without limitation, uncertainty whether L-DOS47 will be developed successfully as a drug or at all; uncertainty whether DOS47 will be developed as a therapeutic for any other cancers; research & development risks, including the risk that early R&D results may not be repeated in later R&D; the risk of technical obsolescence; the need for regulatory approvals, which may not be obtained in a timely matter or at all; the need for clinical trials, the occurrence and success of which cannot be assured; intellectual property risks; marketing/manufacturing and partnership/strategic alliance risks; the effect of competition; Helix's need for additional future capital, which may not be available in a timely manner or at all, as well as a description of other risks and uncertainties affecting Helix and its business, as contained in Helix's latest Annual Information Form and other filings with the Canadian
Securities Regulatory Authorities at www.sedar.com, any of which could cause actual results to vary materially from current results or Helix's anticipated future re
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Helix BioMedix to Discuss Potential of Its Proprietary Peptides at the BIO International Convention
2. Helix BioPharma Corp. Announces Positive Phase II Clinical Results with its Topical Interferon Alpha-2b
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
5. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
6. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Mechanism of Action and Clinical Activity of Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American Diabetes Association 67th Scientific Sessions in Chicago, Illinois
7. Integrated Biopharmas Proprietary Vaccine Technology Achieves Strong Positive Results
8. Accentia Biopharmaceuticals Scientific Presentations Demonstrate Increasing Acceptance of Fungal Etiology of Chronic Sinusitis at the Annual Meeting of the American Academy of Allergy, Asthma, and Immunology
9. The Past, Present and Future of HLA Typing
10. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
11. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:9/19/2014)... DALLAS , Sept. 19, 2014 /PRNewswire-iReach/ ... Chinese Oxybutynin Hydrochloride Industry, 2009-2019 is a ... and Chinese Oxybutynin Hydrochloride industry. The report ... Hydrochloride including its classification, application and manufacturing ... China,s top manufacturers of Oxybutynin Hydrochloride listing ...
(Date:9/19/2014)... , September 19, 2014 ... ) has announced the addition of the ... report to their offering.      ... have been broadly classified into wide categories ... used for the treatment of different gynecological ...
(Date:9/19/2014)... , September 19, 2014 ... by Equipment (Cryotherapy, Heat, therapy, Hydrotherapy), Accessories (Posture Mirror, ... (Hospitals), Advanced technologies - Global Forecast to 2019" ... poised to reach $19,786.3 Million by 2019 from ... 6.8% from 2014 to 2019. Browse ...
Breaking Medicine Technology:Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 2Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 3Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 4Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 5Global Gynecological Devices Market 2014-2018: Key Vendors are Bayer, Boston Scientific, CooperSurgical, Ethicon, Hologic, Medtronic, Olympus and Stryker 2Global Gynecological Devices Market 2014-2018: Key Vendors are Bayer, Boston Scientific, CooperSurgical, Ethicon, Hologic, Medtronic, Olympus and Stryker 3Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 2Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 3Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 4
... 17, 2011 Reportlinker.com announces that a ... its catalogue: Product ... Pipeline Strengthening the In-Vitro Diagnostics and Cardiovascular ... http://www.reportlinker.com/p0397058/Product-Pipeline-in-Medical-Equipment-Market---Robust-Pipeline-Strengthening-the-In-Vitro-Diagnostics-and-Cardiovascular-Devices-Market.html Product Pipeline in ...
... Ala., Feb. 17, 2011 SuccessEHS, a nationally recognized, ... EMR) software vendor, was recently named by the Arkansas ... in accordance with government health care initiatives. ... Arkansas REC are endowed by the Office of ...
Cached Medicine Technology:Reportlinker Adds Product Pipeline in Medical Equipment Market - Robust Pipeline Strengthening the In-Vitro Diagnostics and Cardiovascular Devices Market 2Arkansas REC Selects SuccessEHS as Preferred Vendor 2Arkansas REC Selects SuccessEHS as Preferred Vendor 3
(Date:9/22/2014)... FL (PRWEB) September 22, 2014 ... than 2,000 physicians, today Clearwater Clinical ... ClearSCOPE Endoscope Adaptor for smartphones. ClearSCOPE ... video from virtually any endoscope and smartphone. , ... adaptor in response to frustrations over the cost, ...
(Date:9/22/2014)... On Saturday, September 27, 2014, La Comunidad Hispana ... fair ¡Vive tu vida! Get Up! Get Moving!® This event ... health and wellness for people of all ages and all ... public, will be held at Anson B. Nixon Park, 100 ... pm. , “This is a wonderful event each year ...
(Date:9/22/2014)... Steven Reinberg HealthDay Reporter ... six-year study of people with type 2 diabetes found ... in preventing heart attacks, strokes and deaths. But intensive ... found. For the study, investigators followed nearly 8,500 ... had their blood pressure and blood sugar levels strictly ...
(Date:9/22/2014)... September 22, 2014 At the ... nonprofit Seafood Nutrition Partnership (SNP) announced the successful ... Healthy: A Cardiovascular Risk Reduction Program for Women. ... understand and mitigate their risk of heart disease ... Action, a plan for addressing significant global challenges ...
(Date:9/22/2014)... The Drive Against Domestic Violence ( ... Ben Talei, MD - a Beverly Hills Facial Plastic ... brothers have planned to drive across the country during ... raise funds and awareness for the National Coalition Against ... the American Academy of Facial Plastic & Reconstructive Surgery's ...
Breaking Medicine News(10 mins):Health News:ClearSCOPE 2.0 Endoscope Adaptor for Smartphones Announced; Endoscopic Video Capture Reinvented 2Health News:La Comunidad Hispana Presents Fourth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 2Health News:La Comunidad Hispana Presents Fourth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 3Health News:Tight Blood Sugar Control Doesn't Prevent Strokes in Diabetics: Study 2Health News:Tight Blood Sugar Control Doesn't Prevent Strokes in Diabetics: Study 3Health News:At 2014 Clinton Global Initiative Annual Meeting, Seafood Nutrition Partnership Announces Pilot Program to Reduce Women’s Heart Disease Risks 2Health News:At 2014 Clinton Global Initiative Annual Meeting, Seafood Nutrition Partnership Announces Pilot Program to Reduce Women’s Heart Disease Risks 3Health News:At 2014 Clinton Global Initiative Annual Meeting, Seafood Nutrition Partnership Announces Pilot Program to Reduce Women’s Heart Disease Risks 4Health News:FOX 5 News Story - Dr. Ben Talei a Beverly Hills Facial Plastic Surgeon organizes the Drive Against Domestic Violence & Botox-for-a-Cause as he Drives across the country 2Health News:FOX 5 News Story - Dr. Ben Talei a Beverly Hills Facial Plastic Surgeon organizes the Drive Against Domestic Violence & Botox-for-a-Cause as he Drives across the country 3
... Berger & Grossmann LLP is issuing the following statement regarding the Sunrise Senior Living, Inc. Securities Litigation. , , ... UNITED STATES DISTRICT COURT, ... INC. Master File, SECURITIES LITIGATION ... Relates to: All Cases, ...
... suggests, , , MONDAY, April 20 (HealthDay News) -- Want to live ... manage your stress. , A new study found that those were ... 100, and longevity is thought to run in families. , "We ... set the children of centenarians apart from other people the same ...
... HOLLYWOOD, Calif., April 20 IPC The Hospitalist ... hospitalist physician group practice company, announced today that it will ... on May 4, 2009, after the market close.A conference call ... (2:00 p.m. PT) on May 4, 2009 and will be ...
... "With Hurricanes Katrina, Rita and Ike we ... and healthcare providers navigate through chaos created by ... Davies, M.D., a seasoned critical care physician and ... which enable communication between patients, their physicians, hospitals ...
... with Picoplatin as Second-Line Therapy for Small Cell Lung ... Poniard Pharmaceuticals, Inc. (Nasdaq: PARD ), a ... of its Phase 2 clinical trial of picoplatin in ... were published in the April 20, 2009, print ...
... 20, 2009 Forest Laboratories, Inc. (NYSE: FRX ... announced today that Savella(TM) (milnacipran HCl), a selective serotonin and ... will be shipped to wholesalers on April 24th and will ... Savella was approved by the U.S. Food and Drug Administration ...
Cached Medicine News:Health News:All Persons Who Purchased or Acquired the Common Stock of Sunrise Senior Living, Inc. ('Sunrise') Between February 26, 2004 and July 28, 2006, Inclusive, and Were Damaged Thereby (The 'Class') 2Health News:All Persons Who Purchased or Acquired the Common Stock of Sunrise Senior Living, Inc. ('Sunrise') Between February 26, 2004 and July 28, 2006, Inclusive, and Were Damaged Thereby (The 'Class') 3Health News:Outgoing Nature Could Get You to 100 2Health News:Outgoing Nature Could Get You to 100 3Health News:IPC The Hospitalist Company, Inc. to Report First Quarter 2009 Financial Results 2Health News:PatientCentral Technologies, LLC and VerdaSee Solutions, Inc. Team Up With Congressional Staff in Washington, DC for Disaster Preparedness 2Health News:PatientCentral Technologies, LLC and VerdaSee Solutions, Inc. Team Up With Congressional Staff in Washington, DC for Disaster Preparedness 3Health News:PatientCentral Technologies, LLC and VerdaSee Solutions, Inc. Team Up With Congressional Staff in Washington, DC for Disaster Preparedness 4Health News:Poniard Announces Publication of Results of Picoplatin Phase 2 Study in Journal of Clinical Oncology 2Health News:Poniard Announces Publication of Results of Picoplatin Phase 2 Study in Journal of Clinical Oncology 3Health News:Poniard Announces Publication of Results of Picoplatin Phase 2 Study in Journal of Clinical Oncology 4Health News:Poniard Announces Publication of Results of Picoplatin Phase 2 Study in Journal of Clinical Oncology 5Health News:Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Commercial Availability of Savella(TM) 2Health News:Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Commercial Availability of Savella(TM) 3Health News:Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Commercial Availability of Savella(TM) 4Health News:Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Commercial Availability of Savella(TM) 5Health News:Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Commercial Availability of Savella(TM) 6
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: